Valproic acid suppresses cervical cancer tumor progression possibly via activating Notch1 signaling and enhances receptor-targeted cancer chemotherapeutic via activating somatostatin receptor type II.

MLA

Tsai, Cheguo, et al. “Valproic Acid Suppresses Cervical Cancer Tumor Progression Possibly via Activating Notch1 Signaling and Enhances Receptor-Targeted Cancer Chemotherapeutic via Activating Somatostatin Receptor Type II.” Archives of Gynecology and Obstetrics, vol. 288, no. 2, Aug. 2013, pp. 393–400. EBSCOhost, https://doi.org/10.1007/s00404-013-2762-7.

APA

Tsai, C., Leslie, J. S., Franko-Tobin, L. G., Prasnal, M. C., Yang, T., Vienna Mackey, L., Fuselier, J. A., Coy, D. H., Liu, M., Yu, C., & Sun, L. (2013). Valproic acid suppresses cervical cancer tumor progression possibly via activating Notch1 signaling and enhances receptor-targeted cancer chemotherapeutic via activating somatostatin receptor type II. Archives of Gynecology and Obstetrics, 288(2), 393–400. https://doi.org/10.1007/s00404-013-2762-7

Chicago

Tsai, Cheguo, Juliana S Leslie, Laura G Franko-Tobin, Monica C Prasnal, Tong Yang, L Vienna Mackey, Joseph A Fuselier, et al. 2013. “Valproic Acid Suppresses Cervical Cancer Tumor Progression Possibly via Activating Notch1 Signaling and Enhances Receptor-Targeted Cancer Chemotherapeutic via Activating Somatostatin Receptor Type II.” Archives of Gynecology and Obstetrics 288 (2): 393–400. doi:10.1007/s00404-013-2762-7.